Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Revenue: 2023-2024

Historic Revenue for Entrada Therapeutics (TRDA) over the last 2 years, with Dec 2024 value amounting to $210.8 million.

  • Entrada Therapeutics' Revenue fell 91.75% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.5 million, marking a year-over-year decrease of 71.42%. This contributed to the annual value of $210.8 million for FY2024, which is 63.38% up from last year.
  • Per Entrada Therapeutics' latest filing, its Revenue stood at $210.8 million for FY2024, which was up 63.38% from $129.0 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Revenue registered a high of $210.8 million during FY2024, and its lowest value of $129.0 million during FY2023.
  • In the last 2 years, Entrada Therapeutics' Revenue had a median value of $169.9 million in 2023 and averaged $169.9 million.
  • Data for Entrada Therapeutics' Revenue shows a peak YoY spiked of 63.38% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Entrada Therapeutics' Revenue stood at $129.0 million in 2023, then surged by 63.38% to $210.8 million in 2024.